About NewLeaf Symbiotics
NewLeaf Symbiotics is a Chemicals & Materials company based in St. Louis (United States) founded in 2011 by Stephen Kahn. Crop inputs are supplied using beneficial plant bacteria for agriculture. It operates in the Chemicals & Materials and Agriculture sectors. NewLeaf Symbiotics has raised $181 million across 11 funding rounds from investors including SABIC, Bayer and Monsanto. NewLeaf Symbiotics has completed 1 acquisition, including Intuitive Genomics. Its chief executive, as recorded, is Brent Smith. NewLeaf Symbiotics offers products and services including TS201 Corn Bioinsecticide, Terrasym 450 Corn Biostimulant, Terrasym 401 Soybean Biostimulant, TS601 Biofungicide, and Terrasym 402 Peanut Biostimulant. Its focus areas include Food and Agriculture Tech, Crop Tech, Farm Inputs and Biologicals. Its competitors include Pivot Bio, Ginkgo Bioworks and Kula Bio; 3 of its 3 listed competitors have raised funding.
Company details
NewLeaf Symbiotics was founded in 2011 and is based in St. Louis, United States. Operations focus on the agriculture sector, where crop inputs are developed using Pink Pigmented Facultative Methylotrophs (PPFMs), a family of naturally occurring beneficial plant bacteria. These inputs are applied to seeds at specified concentrations to support plant growth, vigor, health, and yield increases. The company serves farming applications through these microbial solutions.
- Total Equity Funding$181M (USD)
in 11 rounds
- Latest Funding Round$47.01M (USD), Series D
Dec 2023
- InvestorsSABIC
& 12 more
- Investments & Acquisitions
Products & Services of NewLeaf Symbiotics
NewLeaf Symbiotics offers a comprehensive portfolio of products and services, including TS201 Corn Bioinsecticide, Terrasym 450 Corn Biostimulant, Terrasym 401 Soybean Biostimulant, TS601 Biofungicide, and Terrasym 402 Peanut Biostimulant.
Protects corn from pests like CRW to increase yields.
Enhances corn growth and yields through biological application.
Improves soybean productivity in various field conditions.
Controls fungal issues in soybean crops effectively.
Boosts peanut yields by enhancing soil and plant health.
Supports tomato transplant growth for better crop performance.
Apps and channels of NewLeaf Symbiotics
its YouTube channel NewLeaf Symbiotics has 76 subscribers and 30 videos.
Videos from NewLeaf Symbiotics
The most watched videos on NewLeaf Symbiotics's YouTube channel, NewLeaf Symbiotics (76 subscribers). Click a video to play it here.
More on NewLeaf Symbiotics.
Funding Insights of NewLeaf Symbiotics
NewLeaf Symbiotics has successfully raised a total of $181M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $47.01 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $181M
- Total Rounds 11
- Last Round Series D — $47.01M
- First Round $1.18M
(Nov 2011)
- Investors Count 13
Latest 10 of 11 funding rounds of NewLeaf Symbiotics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $47.01M | Series D | – | Gullspang Re:food | |
| Dec 2022 | $6.75M | Series D | – | – | – |
| Dec 2020 | $22M | Series D | – | – | |
| Feb 2020 | $20.52M | Series D | – | Koch Agronomic Services, Leaps by Bayer | – |
| Jan 2020 | $2M | Series C | – | – | – |
| Sep 2017 | $30M | Series C | – | S2G Ventures, Monsanto | |
| Jul 2017 | $24M | Series C | – | Otter Capital, Monsanto | |
| Mar 2017 | $3.55M | Series B | – | – | – |
| Sep 2014 | $17M | Series B | – | Otter Capital | |
| Jan 2013 | $7M | Series A | – | RockPort Capital, Open Prairie Ventures | – |
13 investors in total: 13 institutional.
Investors in NewLeaf Symbiotics
NewLeaf Symbiotics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include SABIC, Bayer and Monsanto.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Limited information is provided about Otter Capital's activities. | ottercapital.com | |||
Stage agnostic venture capital firm | s2gventures.com | Chicago, United States | ||
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
Growth equity investments are made in agrifood system transformation. | refood.co | |||
Stage-agnostic venture capital investments are made in US companies. | rockportcap.com | Boston, United States | ||
Venture capital investing and portfolio management services for accredited investors. | av.vc | |||
Investment in hard tech for planetary health, focusing on materials science, chemistry, and biology. | pangaeaventures.com | |||
Private equity fund management is provided by Open Prairie. | openprairie.com | Effingham, United States | ||
Venture capital investments are directed toward agriculture and food sectors. | lewisandclarkagrifood.com | St. Louis, United States | ||
Manufacturer and supplier of agro-nutrients and fund of funds focused on new material investments | 1965 | sabic.com | Riyadh, Saudi Arabia |
Investor details for NewLeaf Symbiotics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NewLeaf Symbiotics
23 people are tracked at NewLeaf Symbiotics (15 in leadership, 4 in board & advisors, 4 in team).
| Name | Role | Group |
|---|---|---|
Stephen Kahn | Co-Founder | Leadership |
Brent Smith | CEO | Leadership |
C. Michael McFatrich | VP, Business Strategy & Development | Leadership |
David Purschke | VP, Finance | Leadership |
Natalie Breakfield | VP, Research & Discovery | Leadership |
Nicole Phillips | VP of Marketing | Leadership |
Aaron Kelley | Chief Commercial Officer (cco) | Leadership |
Linda Kingston-Pipkins | Manager Of Partner Success | Leadership |
Desmond Jimenez | Chief Product Officer | Leadership |
Anthony Neumann | Director Of Molecular Biology | Leadership |
Allison Jack | Product Technical Director | Leadership |
Molly Edwards | VP And General Counsel | Leadership |
Michael Frodyma | Vice President Manufacturing Operations | Leadership |
Mark Heinrich | Director, Product | Leadership |
David Flack | VP, Business Development | Leadership |
John Pasquesi | Chairman | Board & advisors |
Paul Schickler | Board Member | Board & advisors |
David Prend | Board Member | Board & advisors |
Sanjeev Krishnan | Board Member | Board & advisors |
John Whitteck | Principal Formulation Scientist | Team |
3 more people are available in the full profile.
Complete people profiles for NewLeaf Symbiotics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NewLeaf Symbiotics
NewLeaf Symbiotics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Intuitive Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Custom bioinformatics solutions are provided for genome-scale data analysis. | intuitivegenomics.com | Burlington, United States | 2010 | Dec 2013 | •••• |
Complete acquisition details for NewLeaf Symbiotics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of NewLeaf Symbiotics
4 dated milestones of NewLeaf Symbiotics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded NewLeaf Symbiotics is founded.
- Funding First funding round of $1.2M.
- Acquisition Acquires Intuitive Genomics.
- Funding Latest funding round, Series D, of $47.0M.
Competitors of NewLeaf Symbiotics
NewLeaf Symbiotics has 3 listed competitors in our database, 3 of them funded. They include Pivot Bio, Ginkgo Bioworks and Kula Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pivotbio.com | 2010 | Berkeley, United States | $618.08M | 256 | Nitrogen-fixing microbes for corn crop nutrition are developed and applied. | |
| ginkgobioworks.com | 2008 | Boston, United States | $795.75M | 1,218 | Gene editing-based cultured ingredients are provided for agriculture. | |
| kulabio.com | 2018 | Natick, United States | $71.23M | 12 | Manufacturer of microbial crop nutrition products |
Detailed competitors of NewLeaf Symbiotics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of NewLeaf Symbiotics
The website of NewLeaf Symbiotics (newleafsym.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▼ 5.2% vs previous month
Top companies in Chemicals Tech
3 companies that operate in the same segment as NewLeaf Symbiotics (Chemicals Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Microbe-based plant protection products and yield optimization services are provided. | 2013 | Boston, Massachusetts, United States | USD 1.4 B | 1,316 | ||
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | |||
Sustainable bio-based chemicals are manufactured using a proprietary platform. | 2016 | Houston, Texas, United States | USD 656.05 M | 133 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Newleaf Symbiotics
Complete news archive for NewLeaf Symbiotics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NewLeaf Symbiotics
NewLeaf Symbiotics was founded in 2011.
NewLeaf Symbiotics is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Brent Smith is the CEO of NewLeaf Symbiotics, as recorded in our data.
NewLeaf Symbiotics is a funded company, having raised a total of $181M across 11 funding rounds to date. The company's 1st funding round was a Series A of $7M, raised on Nov 2011.
NewLeaf Symbiotics was founded in 2011 and is based in St. Louis, United States. Operations focus on the agriculture sector, where crop inputs are developed using Pink Pigmented Facultative Methylotrophs (PPFMs), a family of naturally occurring beneficial plant bacteria. These inputs are applied to seeds at specified concentrations to support plant growth, vigor, health, and yield increases. The company serves farming applications through these microbial solutions.
NewLeaf Symbiotics's top competitors include Ginkgo Bioworks, Pivot Bio and Kula Bio.
NewLeaf Symbiotics offers TS201 Corn Bioinsecticide, Terrasym 450 Corn Biostimulant, Terrasym 401 Soybean Biostimulant, TS601 Biofungicide, and 2 more products and services.
NewLeaf Symbiotics has made 1 acquisition, including Intuitive Genomics.
NewLeaf Symbiotics has 13 investors. Key investors include SABIC, Bayer, Monsanto, Otter Capital, and S2G Ventures.
NewLeaf Symbiotics operates through Newleaf Symbiotics.